meloxicam · Iceutica Operations · NDA 207233
Vivlodex
Earliest generic entry, as listed · earliest of 2 marketed strengths
31 Mar 2035
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9649318, US 9808468, US 9808468.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9649318 | product | 31 Mar 2035 |
| US 9808468 | use U-2160 | 31 Mar 2035 |
| US 9808468 | use U-2165 | 31 Mar 2035 |
| US 9526734 | product | 31 Mar 2033 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207233 · 001 · RLD · discontinued | capsule, oral | 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 31 Mar 2035 |
| 207233 · 002 · RLD · discontinued | capsule, oral | 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 31 Mar 2035 |